BRCA1 and cancer: Gene deficiency in any of these DSBRR genes, or ‘BRCAness’, a phenotype first defined in BRCA1/2-mutated cancers, impairs DSB repair and promotes PARPi synthetic lethality (Turner et al., 2004; Tutt, 2018).